Meloxicam
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Meloxicam
- Meloxicam: From NSAID Therapy (Original Indication Not Specified in Evidence Pack) to Acromesomelic Dysplasia, Hunter-Thompson Type
Meloxicam: From NSAID Therapy (Original Indication Not Specified in Evidence Pack) to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Meloxicam’s original approved indication(s) are not recorded in this evidence pack, and no marketing authorisation currently exists in this jurisdiction. The TxGNN model’s top-ranked prediction is Acromesomelic Dysplasia, Hunter-Thompson Type, but this prediction is supported by 0 clinical trials and 0 publications, and the model’s own rationale flags it as a likely false positive.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — evidence pack contains no original_indications or marketing authorisation records |
| Predicted New Indication | Acromesomelic Dysplasia, Hunter-Thompson Type |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Meloxicam in this evidence pack. Based on general pharmacological class knowledge, Meloxicam is a preferential COX-2 inhibitor within the NSAID class, typically used for inflammatory and pain-related musculoskeletal conditions — but this is not confirmed by data provided here.
Critically, the model’s own repurposing rationale for this top-ranked candidate is sceptical rather than supportive. Acromesomelic Dysplasia, Hunter-Thompson Type is a congenital skeletal disorder caused by abnormalities in GDF5 signalling, affecting cartilage development. There is no established biological relationship between this pathway and NSAID/COX inhibition. The evidence pack itself states that this high score is most likely a knowledge-graph artefact — a false positive arising from co-occurrence of skeletal/joint-related nodes in the graph, rather than a genuine mechanistic link.
Given the complete absence of supporting clinical trials or literature, and the model’s own annotation questioning biological plausibility, this specific prediction should not be interpreted as a credible repurposing signal at this time.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
UK Market Information
Meloxicam currently has no recorded marketing authorisations in this evidence pack (market_status: Not marketed; total_licenses: 0). No product-level licence data is available to tabulate.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Acromesomelic Dysplasia, Hunter-Thompson Type) has no supporting clinical trials or literature (Evidence Level L5), and the model’s own mechanistic rationale explicitly identifies it as a probable false positive driven by knowledge-graph node co-occurrence rather than genuine biology. Combined with the absence of UK marketing authorisation and missing safety/MOA data (flagged as a Blocking data gap in the evidence pack), there is no basis to proceed with this specific candidate.
To proceed, the following is needed:
- SmPC warnings, contraindications and DDI data (currently a Blocking data gap — DG001)
- Confirmed mechanism of action and original indication data for Meloxicam (DG002)
- UK marketing authorisation status verification
- Suggested re-focus: Ranks 6–8 in this evidence pack (spondyloarthropathy susceptibility, rheumatoid nodulosis, RF-positive polyarticular juvenile idiopathic arthritis) carry class-level mechanistic plausibility as inflammatory arthropathies consistent with NSAID/COX-2 pharmacology, and are scored at Evidence Level L4 with a “Research Question” recommendation — these merit evaluation ahead of the current top-ranked candidate.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.